Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants

• Published in: The New England journal of medicine Vol. 387; no. 5; pp. 468 - 470
• Main Authors: Takashita, Emi, Yamayoshi, Seiya, Simon, Viviana, van Bakel, Harm, Sordillo, Emilia M., Pekosz, Andrew, Fukushi, Shuetsu, Suzuki, Tadaki, Maeda, Ken, Halfmann, Peter, Sakai-Tagawa, Yuko, Ito, Mutsumi, Watanabe, Shinji, Imai, Masaki, Hasegawa, Hideki, Kawaoka, Yoshihiro
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 04.08.2022
• Subjects: Antibodies, Monoclonal - therapeutic use; Antibodies, Neutralizing - therapeutic use; Antibodies, Viral - immunology; Antiviral agents; Antiviral Agents - therapeutic use; Coronavirus; Coronaviruses; Correspondence; COVID-19; COVID-19 - immunology; COVID-19 Drug Treatment; Disease transmission; Drugs; FDA approval; Humans; Immunologic Factors - therapeutic use; Infectious Disease; Infectious diseases; Influenza; Monoclonal antibodies; Mutation; Pathogenesis; Proteins; R&D; Research & development; RNA polymerase; SARS-CoV-2 - drug effects; Severe acute respiratory syndrome coronavirus 2; Vaccine Efficacy; Viral Infections; United States > US; Japan

In Vitro Activity of Antibodies and Drugs against OmicronIn this study, investigators who were evaluating in vitro neutralization of omicron subvariants by monoclonal antibodies and antiviral drugs found considerable variation among the agents.